Francisco Esteva, director, breast medical oncology program, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the findings of a biosimilar trastuzumab study in patients with HER2-positive breast cancer.
Newsletter
Stay up to date on practice-changing data in community practice.